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TransactivationMineralocorticoid receptor (MR) antagonists decreasemorbidity andmortality in heart failure patients forwhom
oxidative stress is usual; however, the underlying mechanism for this protection is unclear. Since aldosterone
stimulates reactive oxygen species (ROS) production in several tissues, we explored its effect and the intracellular
pathway involved in the ratmyocardium. Aldosterone dose-dependently increasedO2− production inmyocardial
slices. At 10 nmol/L, aldosterone increased O2
− to 165 ± 8.8% of control, an effect prevented not only by the MR
antagonists eplerenone and spironolactone (107 ± 7.8 and 103 ± 5.3%, respectively) but also by AG1478
(105 ± 8.0%), antagonist of the EGF receptor (EGFR). Similar results were obtained by silencing MR expression
through the direct intramyocardial injection of a lentivirus coding for a siRNA against the MR. The aldosterone
effect on O2
− production was mimicked by the mKATP channel opener diazoxide and blocked by preventing its
opening with 5-HD and glibenclamide, implicating the mitochondria as the source of O2−. Inhibiting the respira-
tory chain with rotenone or mitochondrial permeability transition (MPT)with cyclosporine A or bongkrekic acid
also canceled aldosterone-induced O2
− production. In addition, aldosterone effect depended on NADPH oxidase
and phosphoinositide 3-kinase activation, as apocynin and wortmannin, respectively, inhibited it. EGF (0.1 μg/
mL) similarly increased O2−, although in this case MR antagonists had no effect, suggesting that EGFR
transactivation occurred downstream from MR activation. Inhibition of mKATP channels, the respiratory chain,
orMPT did not prevent Akt phosphorylation, supporting that it happened upstream of themitochondria. Impor-
tantly, cardiomyocytes were confirmed as a source of aldosterone inducedmitochondrial ROS production in ex-
periments performed in isolated cardiac myocytes.
These results allow us to speculate that the beneficial effects ofMR antagonists in heart failuremay be related to a
decrease in oxidative stress.
© 2013 Elsevier Ltd. All rights reserved.1. Introduction
The renin–angiotensin–aldosterone system is activated during heart
failure (HF). Mineralocorticoid receptor (MR) antagonists have been
shown to decreasemorbidity andmortality not only in patientswith se-
vere HF [1] and after myocardial infarction [2] but also in patients with
HF class II of the NYHA functional class [3]. The mechanism by which
this inhibition induces beneficial effects, however, has not yet been
completely clarified [4,5]. On the other hand, a deleterious increase in
oxidative stress has been recognized in HF [6–8], and endothelial dys-
function is linked to this abnormality [9].receptor; ROS, reactive oxygen
EGFR, epidermal growth factor
roxydecanoate; CsA, cyclospor-
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ights reserved.A role for aldosterone in increasing reactive oxygen species (ROS)
production in smooth muscle cells, cardiac myocytes, and other tissues
has been reported recently, but the intracellular signaling pathway in-
volved in this phenomenon in the myocardium remains unknown
[10–13]. In the current study, experiments were performed in rat myo-
cardium and isolated cardiac myocytes to analyze in detail the mecha-
nism underlying aldosterone-induced myocardial O2− production. Our
results indicate that aldosterone induces the opening of mitochondrial
ATP-dependent potassium (mKATP) channels via a non-genomic mech-
anism that relies on MR-dependent epidermal growth factor receptor
(EGFR) transactivation, increasing mitochondrial ROS production.
2. Methods
2.1. Animals
All the procedures followed during this investigation conform to the
Guide for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-23, revised 1996)
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Committee of La Plata School of Medicine. Rats (body weight
300–400 g) were anesthetized by intraperitoneal injection of sodium
pentobarbital (35 mg/kg body weight) and hearts rapidly excised
when plane three of phase III of anesthesia was reached.
2.2. Construction and production of lentiviral vectors
DNA encoding for siRNA against theMR (siRNAMR) or the scrambled
sequence (siRNASCR) was inserted in the lentiviral vector backbone
PPT.CDsRed2.H1 as previously described [14]. Sequence for siRNAMR
was obtained from the work of Wang et al. [15] and subcloned, at the
BamHI cloning site (5′) and PacI cloning site (3′), following the H1
RNA Polymerase promoter, to generate PPT.CDsRed2.H1.siRNAMR.
2.3. Injection of lentiviral vector
Four-month-old male Wistar rats were injected with lentivirus at
two sites in the anterolateral wall of the left ventricle as described be-
fore [14]. Four weeks after injection animals were sacrificed, heart re-
moved and sliced. Some slices were used to measure O2− production
and otherswere immediately processed to obtain a protein homogenate
and stored at−70 °C for immunoblot analysis.
2.4. Myocardial slices
Left ventricular myocardial slices (1 × 5 mm) were obtained from
anesthetized 4-month-old male Wistar rats and incubated in Krebs–
Hepes assay buffer as previously described [16].
2.5. Cell isolation
Rat ventricular myocytes were isolated from 4-month-old Wistar
rats according to the technique described previously [17]. Myocytes
were kept in 1 mmol/L CaCl2 K-H solution at room temperature (20–
22 °C) until use.
2.6. Measurement of ROS production
2.6.1. In myocardial slices
Myocardial O2− production was measured by the lucigenin-en-
hanced chemiluminescence method as previously described [16].
Since high lucigenin concentrations (N20 μmol/L) may favor redox cy-
cling, we used 5 μmol/L lucigenin, at which the amount of artifacts has
been proven insignificant [18]. For each intervention evaluated the
lucigenin-chemiluminescence signal was normalized to milligrams of
dry weight tissue per minute and expressed relative to the basal
production.
2.6.2. In isolated cardiomyocytes
Freshly isolated cardiomyocytes were loaded with 10 μmol/L 5-
(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, ace-
tyl ester (CM-H2DCFDA, Invitrogen) in K-H solution for 30 min at
37 °C in dark. This dye is deacetylated intracellularly by non-specific es-
terase, which was further oxidized by cellular peroxides to the fluores-
cent compound 2,7-dichlorofuorescein (DCF), which reported H2O2
levels [19]. Cardiomyocytes were washed with K-H solution to remove
dye excess, placed in six-well plates (a different well for each treat-
ment) and excited at 495 nm. Emission spectra were acquired trough
a 510 nm filter with a Nikon camera attached to an inverted Nikon
Eclipse TE2000-S microscope. Photographs were taken immediately in
control or stimulated cells (aldosterone 10 nmol/L, or EGF 0.1 μmol/L)
every 3 min, during 18 min. The inhibitors and antagonists were placed
10 min before stimulus. Image J software was used for image analysis.
Results of fluorescence (arbitrary units) vs. time were fitted with linealfunction and obtained a slope for each treatment. Results were
expressed as % of control slope.
2.7. Immunoanalysis by Western blot
At the end of the experimental protocols cardiac tissue slices were
homogenized in lysis buffer (300 mmol/L sacarose; 1 mmol/L DTT;
4 mmol/L EGTA, protease inhibitors cocktail (Complete Mini Roche);
20 mmol/L Tris–HCl, pH 7.4) for determination of EGFR and Akt phos-
phorylation; and in 50 mM Tris–HCl, pH 7.4 for NADPH oxidase (Nox)
andMR expression. Sampleswere denatured and equal amounts of pro-
tein were subjected to PAGE and electrotransferred to PVDF mem-
branes. Membranes were then blocked with non-fat-dry milk and
incubated overnight with: anti gp91-phox polyclonal antibody (Santa
Cruz Biotechnology, sc-5827); anti-phospho-EGFR (Tyr1173)monoclo-
nal antibody (Cell signaling Technology # 4407); anti-phospho-Akt
polyclonal antibody (Cell Signaling Technology #4060) or anti-ratMR
(antibody 4G5, kindly provided by Dr. Celso Gomez Sanchez). Antibod-
ies against EGFR (Santa Cruz Biotechnologies sc-03) or Akt (Cell Signal-
ing Technology #9272) respectively were assayed to normalize the
amount of the phosphorylated form to the total content of the corre-
sponding protein, while the detection of GAPDH (Millipore MAB374)
was used as loading control. Peroxidase-conjugated anti-rabbit
(NA934, GE Healthcare Life Sciences) or anti-mouse IgG (NA931, GE
Healthcare Life Sciences) was used as secondary antibodies and bands
were visualized using the ECL-Plus chemiluminescence detection sys-
tem (Amersham). Autoradiograms were analyzed by densitometric
analysis (Scion Image).
2.8. Chemicals
All drugs used in the present study were of analytical reagent. Aldo-
sterone, EGF, lucigenin (5 μmol/L), Tiron (10 mmol/L), nitro-L-arginine
methyl ester (L-NAME 1 mmol/L), 5-hydroxydecanoate (5-HD,
100 μmol/L), rotenone (10 μmol/L), cycloheximide (20 μg/mL), Mifep-
ristone (RU-486; 1 μmol/L), spironolactone (10 μmol/L), KT 5823
(1 μmol/L), wortmannin (10 nmol/L), cyclosporine A (CsA, 0.5 μmol/L)
and bongkrekic acid (10 μmol/L) were purchased from Sigma. PP1
(20 μmol/L) was purchased from Biomol. Eplerenone (10 μmol/L) was
kindly donated by Gador SA, Argentina. Apocynin (300 μmol/L) was
from FLUKA. Glibenclamide (50 μmol/L) was purchased from RBI. AG
1478 (1 μmol/L) and MMP inhibitor (3 μmol/L) were from Calbiochem.
2.9. Statistics
Data are expressed as mean ± SEM. Differences between groups
were assessed by one-way ANOVA followed by Student–Newman–
Keuls test. P b 0.05 was considered significant.
3. Results
We explored the effect of aldosterone on cardiac O2− production by
the lucigenin-enhanced chemiluminescence method in myocardial
slices [16]. Aldosterone induced a dose-dependent increase in the
lucigenin-chemiluminescence signal indicating a stimulatory effect of
the hormone on myocardial O2− production (Fig. 1A). To investigate
the underlying signaling pathway involved in this effect as well as the
source of O2−, we performed experiments to evaluate the influence of
10 nmol/L aldosterone in the presence of different inhibitors. This con-
centration of aldosterone is one of the most frequently used for in vitro
studies [10,11,20,21] and showed submaximal stimulation of O2− pro-
duction. Absolute baseline values among groups were not statistically
different (Supplemental Fig. 1). Two different MR antagonists,
spironolactone and eplerenone completely blocked the increased O2−
production induced by aldosterone. Notably, the glucocorticoid receptor
antagonist RU-486 (mifepristone) had no effect. Interestingly, the effect
Fig. 1. (A) Aldosterone induced a dose-dependent increase inmyocardial O2− production. *p b 0.05 vs. control (C); #p b 0.05 vs. aldosterone 10 nmol/L; ANOVA. (B) The increase inmyo-
cardial O2− production induced by aldosterone (10 nmol/L)was completely preventedby twodifferent antagonists of themineralocorticoid receptor, the nonselective spironolactone (Sp)
and the highly selective eplerenone (Epl), but unaffected by an antagonist of the glucocorticoid receptor, mifepristone (RU-486). Moreover, the aldosterone effect was not modified by
preventing protein synthesis with cycloheximide (Chx). Aldosterone-induced O2− production depended on NADPH oxidase (Nox) activity as demonstrated by its prevention with
apocynin (Apo). None of the inhibitors assayed had an effect on myocardial O2− production without aldosterone (Sp 222.1 ± 21.86, n = 6; Epl 230.5 ± 18.53, n = 4; RU-486
233.2 ± 19.23, n = 4; Chx 247.6 ± 24.21, n = 4; Apo 237.6 ± 13.18, n = 7). (C) Under our experimental conditions aldosterone did not exert an effect uponNox expression, reinforc-
ing the notion that the increase in O2− production was the consequence of a non genomic effect. (D) The silencing of the MR obtained by a direct intramyocardial injection of a lentivirus
encoding for siRNAMR canceled the aldosterone-inducedmyocardial O2− production, effect not detectedwhen the ratswere injectedwith the same lentivirus but encoding for the scramble
sequence (siRNASCR). *p b 0.05, ANOVA. Inset: Myocardial MR expression normalized to the amount of GAPDH in siRNASCR (black bar) and siRNAMR (grey bar) injected rats.*p b 0.05, t-
test. The number of samples included in each group is depicted over the corresponding bar.
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by cycloheximide, supporting that this was a non-genomic effect of
the hormone. Apocynin inhibited aldosterone-induced O2− production,
suggesting the latter's dependence on Nox activity (Fig. 1B). In agree-
mentwith the cycloheximide data, Nox contentwas notmodified by al-
dosterone under our experimental conditions, reinforcing the notion
that the increase in O2− production was the consequence of a non-ge-
nomic effect (Fig. 1C).
Since pharmacological MR inhibitors may have effects not related to
MR blockade [22,23], aldosterone-induced myocardial O2− production
was also tested after silencing theMRwith siRNA technology. A lentivi-
rus encoding for the fluorescent protein DsRed plus the siRNAMR or
DsRed plus siRNAscr was injected into the left ventricular wall following
an experimental protocol that we have previously used successfully to
silence myocardial Na+/H+ exchanger [14]. After 4 weeks of the
lentiviral injection and in order to confirm the spreading of the lentivirus,
we assessed DsRed fluorescence on histological sections of siRNAMR- and
siRNAscr-injected rat hearts, as well as on non-injected hearts used as
controls. Representative confocal images are shown in Supplemental
Fig. 2. Similar to the results obtained when measuring MR protein ex-
pression by Western blot, the DsRed signal reveals a patchy distribution
approximately affecting 50% of themyocardiumof the lentiviral-injected
hearts while no signal was detected in the sham operated ones. At thistime point, aldosterone was unable to increase myocardial O2− produc-
tion despite the modest decrease in myocardial MR protein expression
(Fig. 1D). The effectiveness of the technique used to silence the myocar-
dial MR might be enhanced by the spread of the siRNA from cell to cell
through connexins, as proposed by Kizana et al. [24] Taken together,
these results suggest that aldosterone stimulates Nox-inducing myocar-
dial O2−production and that this effect depends onMRbut not on protein
synthesis.
Because the mitochondria is the main source of stimulated myocar-
dial O2− production and small amounts of Nox-produced O2− favors mi-
tochondrial production/release of greater amounts of O2− [25], we
designed a new set of experiments to explore mitochondrial involve-
ment in the mechanism triggered by aldosterone. Either 5-HD or
glibenclamide was used to prevent mKATP channel opening and rote-
none was applied to inhibit complex I of the respiratory chain. Each of
these treatments blocked aldosterone-induced myocardial O2− produc-
tion. Furthermore, when the MPT induction was prevented by cyclo-
sporine A no increase in myocardial O2− was detected; confirming the
mitochondrial origin of O2− (Fig. 2A). In order to confirm the relevance
of the MPT in aldosterone-induced O2− production, and since cyclo-
sporine A also inhibits the phosphatase calcineurin which might have
an impact on the signaling cascade per se [26], the effect of bongkrekic
acid – another MPT blocker – was assessed. Similar to the results
Fig. 2. (A) The mitochondria were revealed as the source for O2− induced by aldosterone
because its production was canceled by preventing mKATP channel opening with either
5-hydroxydecanoate (5-HD) or glibenclamide (Gli) as well as by inhibiting complex I of
the respiratory chain with rotenone (Rot) and the mitochondrial permeability transition
pore opening with cyclosporine A (CsA) or bongkrekic acid (BKA). (B) The opening of
mKATP channels with diazoxide (100 μmol/L) increased myocardial O2˙−production at a
similar magnitude to aldosterone (10 nmol/L). Diazoxide-induced ROS production was
canceled by 5-HD, Gli, Rot and CsA but not by Apo. None of the inhibitors assayed had
an effect on myocardial O2− production without aldosterone or diazoxide (Apo
237.6 ± 13.18, n = 7; 5-HD 226.6 ± 15.18, n = 5; Gli 198.4 ± 8.37, n = 3; Rot
232.6 ± 8.42, n = 4; CsA 224.5 ± 11.59, n = 8; BKA 221.2 ± 10.74, n = 3). The num-
ber of samples included in each group is depicted over the corresponding bar. *p b 0.05
vs. control (C); ANOVA.
Fig. 3. EGFR transactivationwas involved in aldosterone-inducedmyocardial O2− production.
AG-1478, an antagonist of the EGFR; PP1, an inhibitor of the c-Src kinase and MPI, a broad
spectrummetalloproteinase inhibitor abolished aldosterone (10 nmol/L)-inducedmyocardi-
al O2− production. It is important to highlight that AG1478, PP1 andMPI alone did notmodify
basal myocardial O2− production (239.9 ± 12.32, n = 5; 237.3 ± 7.43, n = 4 and
206.2 ± 9.5, n = 4, respectively). The number of samples included in each group is depicted
over the corresponding bar. *p b 0.05 vs. control (C); ANOVA.
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effect of aldosterone uponmyocardial O2− production (Fig. 2A). These re-
sults are in line with previous reports supporting that Nox-dependent
O2− production triggers the opening of mKATP channels inducing mito-
chondrial depolarization and subsequentmitochondrial ROS generation,
by the so-called “ROS (reactive oxygen species)-induced, ROS-released
phenomenon” [25,27,28]. To provide further support for the proposal
that the opening of mKATP channels represents a critical step in the aldo-
sterone-triggered signaling pathway leading to O2− production, we per-
formed experiments using 100 μmol/L diazoxide, a widely accepted
mKATP channel opener. Diazoxide induced an increase in myocardial
O2− production similar to that induced by 10 nmol/L aldosterone, but in
this case, it was apocynin insensitive. Diazoxide-induced ROS production
was blocked by themKATP channel blockers 5-HD and glibenclamide, in-
hibition of the respiratory chain with rotenone, and prevention of MPT
with cyclosporine A (Fig. 2B). These results suggest that aldosterone trig-
gers O2− production of mitochondrial origin through the opening of
mKATP channels.
Recent evidence supports that MR activation elicits its non-genomic
effects in smooth and cardiac muscle cells at least in part by
transactivation of the EGFR [29–32]. Moreover, aldosterone activates
metalloproteinases that can induce the ectoshedding of the HB-EGF li-
gand for the EGFR [10,32]. Therefore, we explored the involvement of
EGFR transactivation in aldosterone-induced myocardial O2−production. As Fig. 3 shows, AG1478, an antagonist of the EGFR,
abolished the effect of 10 nmol/L aldosterone onO2−production. This ef-
fectwas also abolished by PP1, an inhibitor of the c-Src kinase previous-
ly implicated in angiotensin II-induced EGFR transactivation [33]; and
by MPI, a broad-spectrum metalloproteinase inhibitor [34].
Aldosterone-induced EGFR transactivation was confirmed by Western
blot. As it can be appreciated in Fig. 3B, 10 nmol/L aldosterone signifi-
cantly increased EGFR autophosphorylation, an effect prevented not
only by eplerenone but also by MPI. Once we found that EGFR
transactivation was required for aldosterone-induced myocardial O2−
production we explored the effect of exogenously administered EGF
on O2− production. A dose–response curve showed that 0.1 μg/mL
EGF increasedmyocardial O2− production to levels similar to those elic-
ited by 10 nmol/L aldosterone (Fig. 4). Inhibition of the EGFR with
AG1478 suppressed the effect of exogenous EGF, but Src kinase inhibi-
tion with PP1did not, supporting the idea that aldosterone activates
Src upstream EGF binding to EGFR in the chain of events leading to
Fig. 5. Both aldosterone (Ald)- and EGF-induced myocardial O2− production were
preventedby inhibition of the PI3K/Akt pathwaywithwortmannin (Wort). PKG inhibition
with 1 μmol/L KT5823 (KT) only partially diminished stimulated mitochondrial O2− pro-
duction. KT5823 or Wort alone did not modify basal O2− production (230.8 ± 6.38,
n = 3 and 212 ± 8.96, n = 4, of control respectively). The number of samples included
in each group is depicted over the corresponding bar. *p b 0.05 vs. Ald or EGF, respective-
ly; #p b 0.05 vs. Ald or EGF plus Wort, respectively; ANOVA.
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triggered by the activated EGFR conducting to mitochondrial ROS pro-
duction under our experimental conditions. Apocynin prevented the ef-
fect of EGF indicating its dependence onNox activation. Furthermore, 5-
HD, glibenclamide, and rotenone inhibited EGF-stimulated O2− produc-
tion, confirming that the mitochondria were the source for the increase
in O2− (Fig. 4).
As noted above, it has been suggested that small amounts of cytosol-
ic Nox-dependent O2− production induce the opening of the mKATP
channel and further mitochondrial O2− generation through a “ROS in-
duced ROS release” phenomenon [25,27,35]. Downey's group proposed
an alternative mechanism for the opening of the mKATP channels after
EGFR transactivation that involves the PI3K/Akt pathway, nitric oxide
synthase (NOS), and protein kinase G (PKG) [36]. Therefore, we exam-
ined the possible involvement of this pathway in aldosterone-induced
mitochondrial O2− production. Wortmannin, an inhibitor of PI3K/Akt,
prevented both aldosterone- and EGF-induced mitochondrial O2− pro-
duction; but PKG inhibition (1 μmol/L KT5823) diminished the stimu-
lated O2− production by only about 50%. Increasing the concentration
of KT5823 to 5 μmol/L yielded no additional inhibitory effect (aldoste-
rone 43 ± 7%, n = 3 and EGF 47.3 ± 8%, n = 3 over control),
supporting that PKG inhibition with this pharmacologic compound
was at its maximal effect (Fig. 5). Moreover, NOS inhibition with
L-NAME also partially diminished aldosterone-stimulated O2− produc-
tion (163.1 ± 5.5, n = 8 vs. 134.8 ± 5.9, n = 5; p b 0.05 for aldoste-
rone and aldosterone + L-NAME respectively), suggesting that PKG
and NOS have a role in this signaling pathway. Further studies will be
necessary to elucidate the precise mechanism and relevance of NO
and PKG-dependent pathway in aldosterone-induced mitochondrial
O2− production.
Since myocardial slices are multicellular preparations composed not
only by cardiomyocytes but also smooth muscle cells, endothelial cells
and fibroblasts; a new set of experiments was performed in isolated car-
diac myocytes in order to confirm that the stimulatory effect of aldoste-
rone on ROS production specifically developed in the cardiomyocytes.
Freshly isolated rat ventricularmyocyteswere incubated in the presence
of 10 nmol/L aldosterone alone or in combination with spironolactone,
AG1478, 5-HD, rotenone or bongkrekic acid. ROS production was mea-
sured by DCF fluorescence. Aldosterone increased H2O2 production in
isolated cardiomyocytes similar to what was detected in ventricularFig. 4. Exogenously administered EGF dose-dependently stimulated myocardial O2− pro-
duction, with a concentration of 0.1 μg/mL EGF equipotent to 10 nmol/L aldosterone. As
expected, EGF action was suppressed by the EGFR antagonist AG1478 but not affected
by inhibition of Src kinase with PP1, supporting that Src was activated upstream of EGF
binding to EGFR. The EGF effect depended on Nox activation as revealed by its prevention
with apocynin (Apo), and again the source of O2−was demonstrated to be the mitochon-
dria because its production was blunted by 5-HD, Gli and Rot. None of the inhibitors
assayed modified basal myocardial O2− production (AG 239.9 ± 12.32, n = 5; PP1
237.3 ± 7.43, n = 4; Apo 237.6 ± 13.18, n = 7; 5-HD 226.6 ± 15.18, n = 5; Gli
198.4 ± 8.37, n = 3; Rot 232.6 ± 8.42). The number of samples included in each group
is depicted over the corresponding bar. *p b 0.05 vs. control (C); #p b 0.05 vs. 0.1 μg/mL
EGF; ANOVA.slices (~50%). This effect was prevented not only by antagonizing the
MR with spironolactone but also by inhibiting EGFR activation with
AG1478, preventing mKATP channel opening with 5-HD, inhibiting com-
plex I of the respiratory chain with rotenone and preventingMPT induc-
tion with bongkrekic acid (Fig. 6). Moreover, experiments performed
assessing dihydroethidium (DHE) fluorescence indicated that aldoste-
rone stimulated O2− production by the isolated cardiomyocytes (Supple-
mental Fig. 3). Exogenous EGF (0.1 μg/mL) also increased H2O2
production in isolated cardiomyocytes, effect that was prevented by
AG1478 but not by the blockade of the MR. These data support that the
MR and the EGFR are sequentially and unidirectional activated in the iso-
lated myocytes, being the former upstream the later (Fig. 6).
The involvement of PI3K/Akt in the aldosterone-triggered intracel-
lular signaling pathway was confirmed by assessing myocardial Akt
phosphorylation by immunoblot. Aldosterone increased Akt phosphor-
ylation, an effect that was prevented by antagonizing the MR with
eplerenone or spironolactone and by impeding EGFR transactivation
with AG1478 or PI3K activation with wortmannin. Nevertheless, and
in contrast to the results obtained for O2− production, Akt phosphoryla-
tion was neither affected by precluding mKATP channel opening nor by
inhibiting the mitochondrial respiratory chain with rotenone or MPT
with bongkrekic acid, confirming that the activation of this kinase
occurs upstreamof themitochondria (Fig. 7). None of the pharmacolog-
ical inhibitors modified AKT phosphorylation when used alone
(eplerenone 105.6 ± 9.2%, n = 3; AG1478 101.8 ± 1.6%, n = 5; rote-
none 93.5 ± 8.5%, n = 7; 5-HD 85.1 ± 9.8%, n = 7; CsA 86.6 ± 11.5%,
n = 7; bongkrekic 112.4 ± 13.8%, n = 5; wortmannin 103.5 ± 9.48%,
n = 3).4. Discusion
In the present work we provide pharmacological and molecular evi-
dence that aldosterone increases Nox-dependent myocardial O2− and
H2O2 production of mitochondrial origin through intracellular signals
that lead to the opening of mKATP channels. We detected O2− production
by the lucigeninmethod inmyocardial slices and H2O2 production by the
DCF method in isolated ventricular myocytes. These effects were
prevented not only by pharmacologically antagonizing the MR but also
by themolecular silencing of the receptor. TheopeningofmKATP channels
would allow K+ entry, mitochondrial swelling and MPT induction in-
creasingO2−production [37–39]. These ROS leave themitochondria prob-
ably asH2O2, becauseO2− is a short-lived, unstable compound that rapidly
generates H2O2 through spontaneous and enzymatic dismutation.
Fig. 6. In isolated cardiacmyocytes both aldosterone (10 nmol/L) and EGF (0.1 μg/mL) increasedROS (H2O2) production similarly to the effect detected inmyocardial slices, confirming the
cardiomyocytes themselves not only as targets of these agonists but also as the source of ROS. (A) Representativemicrographs of DCF-loaded isolated cardiomyocytes in control condition
and after 18 min incubation with aldosterone or EGF. (B) Representative DCF ratios of fluorescence for one control, one aldosterone- and one EGF-stimulated ventricular myocytes,
expressed as the slope of the signal measured every 3 min during 18 min. (C) Aldosterone significantly increased cardiomyocyte H2O2 production, effect that was completely prevented
by: the antagonist of themineralocorticoid receptor spironolactone (Sp); the antagonist of the EGFR, AG-1478; the prevention ofmKATP channel openingwith 5-HD, the inhibition of com-
plex 1 of themitochondrial respiratory chainwith rotenone (Rot) or the inhibition of themitochondrial permeability transitionwith bongkrekic acid (BKA), confirming the results obtain-
ed in myocardial slices. (D) EGF exerted a similar effect to aldosterone in isolated DCF-loaded cardiomyocytes that was prevented by AG-1478 but not by MR antagonism with
spironolactone, supporting the unidirectional signaling pathway in which MR stimulation is upstream of EGFR transactivation and ROS production. Bars are the mean ± SE of the
slope of DCF signal for each experimental group expressed as percentage of non-stimulatedmyocytes. The number of myocytes assayed in each group is depicted over the corresponding
bars. *p b 0.05 vs. control; ANOVA. None of the inhibitors assayed had a significant effect on cardiomyocyte DCF fluorescence in the absence of aldosterone (Sp 83 ± 23%, n = 7; AG1478
103 ± 20%, n = 6; 5-HD 88 ± 19%, n = 6; Rot 93 ± 28%, n = 6; BKA 71 ± 11%, n = 7 compared to control).
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by this mechanism induces HB-EGF ectoshedding and activation of
EGFR. Binding of the released EGF to the EGFR causes dimerization
and transphosphorylation of receptor's tyrosine residues. The redox
sensitive Src kinase has been reported to be involved both as an up-
stream step as well as a downstream target of EGFR transactivation
[30,33,40,41,34,42] However, our results, in agreement with others,
support that Src activation was necessary for aldosterone-induced
EGFR transactivation, probably through MMP activation [43].
EGFR transactivation leads to PI3K activation. Our experiments
demonstrated that wortmannin inhibition of PI3K abolishes
aldosterone-induced mitochondrial O2− production and Akt phos-
phorylation. Wortmannin also abolished EGF-stimulated mitochon-
drial O2− production.
The scheme in Fig. 8 summarizes the proposed signaling pathway by
which aldosterone leads to increased mitochondrial O2−/H2O2 produc-
tion in the myocardium.
The effect of aldosterone increasing myocardial ROS production has
been previously reported [10,11], however, those authors proposedNox
as the source of ROS, and the potential participation of themitochondria
was not explored or even excluded. Also in contrast with the current re-
sults, Rude et al. [10] proposed that the activation of matrix metallopro-
teinaseswas the result of the increased ROS instead of being a necessary
step for aldosterone-induced O2−/H2O2 production.Our data demonstrate that aldosterone-induced myocardial
O2−/H2O2 production was canceled by two different pharmacologic in-
hibitors of the MR, namely spironolactone and eplerenone. However, a
recent report by Gros et al. [22] drew attention to the fact that these
chemical compounds are capable of abolishing effects other than
thosemediated by theMR. Therefore, definitive evidencewas necessary
to confirm the MR-dependence of aldosterone-induced O2− production.
To this aim, we performed experiments silencing the cardiac MR by
direct intramyocardial injection of a lentiviral vector coding for a
siRNA against the MR in which we confirmed that aldosterone-
induced O2− production was an MR-dependent effect (see Fig. 3).
These results are in agreement with a recent report from Fraccarollo
et al. [12] in which they showed that cardiomyocyte-specific inactiva-
tion of the MR gene ameliorated adverse remodeling after myocardial
infarction by attenuating mitochondrial oxidative stress among the
main mechanisms. The experiments performed in isolated cardiac
myocytes support that these cells are the target for aldosterone and
the source of aldosterone-induced ROS production. However, we do
not rule out the involvement of other cell types in response to aldoste-
rone in the intact myocardium.
We highlight several important points to discuss related to the
data presented here supporting that aldosterone induces mitochon-
drial O2−/H2O2 production by EGFR transactivation-dependent mKATP
channel opening in the myocardium. First is the mechanism by which
Fig. 7. Aldosterone increased Akt phosphorylation, and the effect that was prevented not
only by theMR antagonists, eplerenone (Epl) or spironolactone (Sp) but also by impeding
EGFR transactivation with AG1478 or PI3K activation with wortmannin (Wort). However,
in contrast to the data obtained for O2− production, Akt phosphorylation was not affected
by preventing mKATP channel opening (5-HD or glibenclamide, Gli) or by inhibiting the
mitochondrial respiratory chainwith rotenone (Rot) or permeability transition poreopen-
ing with bongkrekic acid (BKA). These results confirm that the activation of this kinase oc-
curs upstream of the mitochondria. (A) A representative immunoblot with one band
corresponding to each experimental group while (B) depicts mean ± SEM of the experi-
mental groups. The number of samples included in each group is over the corresponding
bar. *p b 0.05 vs. Aldosterone or EGF, respectively; ANOVA.
Fig. 8. Schematic summary of the signaling pathwayproposed to be triggered by aldosterone
in themyocardium leading to an increase inmitochondrial O2− production.We can speculate
that the opening of mKATP channels, preceding the increase inmitochondrial O2− production,
is the result of the “ROS-inducedROS release”phenomenon since apocynin (Apo) completely
abolished mitochondrial O2− production. The role played by PKG would probably be to in-
crease the sensitivity of mKATP channels to ROS; however further research would be neces-
sary to completely elucidate the mechanism involved as well as its relevance.
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of the increased myocardial O2− production induced by aldosterone
and EGFwould suggest that a localized Nox-dependent ROSproduction,
close to themitochondria but not detected by the lucigeninmethod (for
review see [44]), would be responsible for opening these channels.
Moreover, Akt activates NADPH oxidase in vitro by site-specific phos-
phorylation of p47phox subunit [45].
Nox2 and Nox4 are the Nox isoforms primarily expressed in
cardiomyocytes (for review see [46]). It seems reasonable to speculate
that Nox2 is most likely involved in the current pathway, because it is
apocynin-sensitive. Nox4 has been recently described as primarily
expressed in cardiac mitochondria; however it is not sensitive to
apocynin and not regulated by post-translational modifications [47].
The immediate product of Nox enzymes is O2−, but because of both
spontaneous and enzymatic dismutation H2O2 is also rapidly generated
from this short-lived, unstable compound, as noted. O2− production oc-
curs either in the extracellular space or in an intraorganelle space.
“Redoxosomes” [48] close to the mitochondria could yield a localized
production of O2− or H2O2 capable of inducingmKATP opening andmito-
chondrial ROS production. Although the O2− does not easily permeate
the bilayer membranes, passage through the membrane may occur
through anion channels pores in some cases. In vitro experiments con-
ducted in mKATP channels reconstituted into planar lipid bilayers have
demonstrated that O2− activates these channels probably by direct ac-
tion on the sulfhydryl groups of the channel protein [49]. In 2000
Zorov et al. [28] proposed in isolated cardiac myocytes that a source of
ROS was able to triggered, through MPT induction, a mitochondrial
burst of ROS production derived from the electron transport chain and
termed this novel phenomenon “ROS-induced ROS release”. Even
though the involvement of the mKATP channels in the “ROS-inducedROS release” phenomenon was not explored at that time, it was later
confirmed by others [25].
In addition to the direct opening of mKATP channels by ROS, another
mechanism has been proposed to explain the opening of mKATP chan-
nels. Investigators analyzing the cardioprotective effect of Gi-coupled
receptor agonists proposed that EGFR transactivation stimulates the
PI3K/Akt pathway and nitric oxide production leading to a PKG-
mediated opening of mKATP channels and increased O2− production
[50–52]. At this point, whether PKG directly phosphorylates mKATP
channels to open them or instead activates some intermediate is un-
clear. Our results showing that PKG inhibition can diminish but not
fully suppress aldosterone-induced mitochondrial O2− production are
in agreement, at least partially, with the above-described findings.
The possibility of both ROS and PKG participating in the opening of
mKATP channels after exposing the myocardium to aldosterone deserves
consideration. In our case, we can speculate, based on the fact that
apocynin completely abolished aldosterone-induced mitochondrial O2−
production, that PKG activation essentially increases the sensitivity of
mKATP channels to O2− favoring their opening. Further research would
be needed to completely clarify the relative importance of each of these
mechanisms.
Also important and independent of the mechanism mediating
mKATP channel opening is the involvement of MPT in the aldosterone-
response. Cyclosporine abolished aldosterone-induced O2− production
in the current work (Fig. 2). Contrary to previous ideas, MPT induction
does not necessarily imply a fatal breakdown of mitochondrial
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normal phenomenon, at least when the duration is short [28,39]. Tran-
sient openings of this pore stimulate a quantal mode of O2− production
by the respiratory chain, called “superoxide flashes”, in diverse cell
types under resting conditions that are controlled by a novel functional
coupling between the MPT and the complexes of the respiratory chain
[39]. Because of this functional coupling, we might expect that the in-
creased O2− production induced by mKATP channel opening would be
linked to MPT pore formation and opening.
The experiments described herein provide insight into the mecha-
nism by which aldosterone increases myocardial O2− production,
allowing these results for some speculation about putative clinical impli-
cations. If aldosterone increasesmyocardial O2− production, inhibition of
theMR would prevent oxidative stress, a widely recognized deleterious
feature in HF. Furthermore, experiments in animal models suggest that
NHE-1 activation is harmful in HF having its inhibition beneficial conse-
quences [53–56]. Additionally, the activation of NHE-1 by ROS is well
validated [16,41,57,58]. Moreover, recent experiments from our lab-
oratory demonstrate that aldosterone increases NHE-1 activity likely
by the same intracellular pathway as that described here, leading to
mitochondrial O2− production [32]. Therefore, it seems reasonable to
speculate that aldosterone inhibition might “deactivate” the ROS-
induced NHE-1 activation and by this mechanism at least partially
contribute to the beneficial effects of MR antagonists.
It is interesting and puzzling that the intracellular signals reported
herein to explain the increase inmitochondrial ROS production induced
by aldosterone are similar to those proposed to underlie myocardial
protection from ischemia-reperfusion injury by pre/post-conditioning
[36]. We think that at least two aspects may be critical in determining
these opposing consequences: a—thewholemap of signalingmolecules
activated by the stimulus; and b—the amount ofmitochondrial ROSpro-
duced. It is interesting to note that in the case of ischemia-reperfusion
injury protection mKATP were proposed to be activated by PKG while
in our case PKG pharmacologic inhibition only partially inhibited aldo-
sterone effect. Moreover, aldosterone induced mitochondrial ROS pro-
duction was completely abrogated by preventing EGFR activation with
AG1478, while the protection brought about by preconditioning by a
similar pathway was not [51].
With respect to the amount of ROS produced, we can speculate that
small quantities possibly trigger protective signaling pathways [59],
while greater amounts favorMPT induction and cardiac damage.We ev-
idenced that aldosterone induces MPT opening while in the case of car-
diac protection the prevention of MPT induction seems to be critical.
5. Conclusions
In the present work pharmacological andmolecular evidence is pro-
vided supporting that aldosterone stimulates Nox-dependent myocar-
dial O2− and H2O2 production of mitochondrial origin through EGFR
transactivation and intracellular signals that lead to the opening of
mKATP channels. Aldosterone effect was blocked not only by pharmaco-
logically interferingwith theMRbut also by genetically silencing this re-
ceptor. Since MR antagonists, by a not yet elucidated mechanism,
decreasemorbidity andmortality in heart failure patients for whom ox-
idative stress is usual, it seems reasonable to speculate that a decrease in
myocardial oxidative stress is implicated in the cardiac beneficial effects
of MR antagonist.
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